Testing Bisoprolol in Patients with Acute or Recurrent Pericarditis to Reduce Symptoms and Prevent Recurrence

3 1 1 1

What is this study about?

This study is looking at pericarditis, which is a condition where the tissue surrounding the heart becomes inflamed. Pericarditis can occur for the first time (acute) or can come back after treatment (recurrent). The medication being tested in this study is bisoprolol, which belongs to a group of medicines called beta-blockers that work by slowing down the heart rate and reducing the workload on the heart.

The purpose of this study is to find out if bisoprolol can help reduce symptoms of pericarditis and prevent the condition from coming back. The study will look at whether the treatment helps symptoms go away within two and four weeks, and whether it lowers the chances of the condition returning within twelve months. Participants will receive bisoprolol at a dose of 1.25 milligrams daily, taken by mouth, for a period of up to 28 days.

During the study, patients will be monitored to see how their symptoms change over time. The study will track whether chest pain and other symptoms continue at different time points, including at one, two, and four weeks. The study will also follow participants for twelve months to see if pericarditis comes back. Additionally, the study will examine the relationship between certain blood test results that show inflammation and heart rate measurements taken at the beginning of the study.

1 Initial enrollment and treatment start

Upon joining the study, treatment will begin within 48 hours of the onset of symptoms related to pericarditis (inflammation of the tissue surrounding the heart).

The study medication is bisoprolol, which belongs to a group of medicines called beta-blockers that help reduce heart rate and workload on the heart.

The medication will be taken by mouth (oral use).

The specific dosage and frequency of bisoprolol administration have not been detailed in the available information.

2 First follow-up assessment

At 2 weeks after starting treatment, an assessment will be conducted to evaluate whether symptoms of pericarditis are still present.

This evaluation will help determine how well the treatment is working in reducing symptoms.

3 Second follow-up assessment

At 4 weeks (1 month) after starting treatment, another assessment will be performed.

This visit will check for the persistence of symptoms and monitor the response to the medication.

4 Long-term monitoring period

Monitoring will continue for up to 12 months after starting treatment.

During this period, assessments will focus on identifying any recurrence (relapse) of pericarditis symptoms.

The frequency of relapses will be tracked throughout this 12-month period.

Who Can Join the Study?

You must have acute pericarditis, which is a sudden inflammation of the tissue surrounding the heart, or recurrent pericarditis, which means the inflammation has come back after a previous episode. The cause of the inflammation can be any reason.
Your symptoms must have started within the last 48 hours, meaning two days or less.
You must be at least 18 years old or older.
You must be able to provide informed consent, which means you understand the study and agree to take part in it.
You must be willing to follow all the procedures required by the study.
Both men and women can participate in this study.

Who Cannot Join the Study?

The source data does not provide specific exclusion criteria (reasons why patients cannot participate) for this clinical trial
Without detailed exclusion criteria listed in the trial information, it is not possible to identify specific conditions, medications, or situations that would prevent participation
Typically, clinical trials have exclusion criteria such as certain medical conditions, medications being taken, allergies, pregnancy status, or other factors, but these are not specified in the available information

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country
Azienda Sanitaria Universitaria Giuliano Isontina	Trieste	Italy
ASST Fatebenefratelli Sacco	Milan	Italy
Azienda Sanitaria Universitaria Friuli Centrale	Udine	Italy
Ospedale Maria Vittoria – Azienda Sanitaria Locale “Città di Torino”	Turin	Italy
Agdsemd Oxrwetmsmka Uviupefirhasb Cwgpfjhhefvc Dxkzb Sexutz E Dylqe Sziiqww Db Tijhjl	Turin	Italy

Trial status

Country	Status	Recruitment Start
Italy	Recruiting	01.10.2025

Trial locations

Investigated drugs:

Bisoprolol

Bisoprolol is a medication that belongs to a group of medicines called beta-blockers. It works by slowing down the heart rate and reducing the force with which the heart pumps blood. In this trial, bisoprolol is being tested to see if it can help reduce symptoms of pericarditis (inflammation of the tissue surrounding the heart) and prevent the condition from coming back.

Pericarditis – Pericarditis is an inflammation of the pericardium, which is the thin, two-layered, fluid-filled sac that surrounds the heart. The condition causes chest pain that may feel sharp or stabbing, and it often worsens when breathing deeply or lying down. The inflammation can develop suddenly and may be accompanied by fever and a general feeling of being unwell. In some cases, fluid can accumulate between the layers of the pericardium, putting pressure on the heart. The condition may resolve after a few weeks, but some people experience recurring episodes where the inflammation returns. Symptoms typically include chest discomfort, difficulty breathing, and sometimes a rapid heartbeat.

Trial ID:

2025-523015-11-00

Protocol code:

BIP

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Testing Bisoprolol in Patients with Acute or Recurrent Pericarditis to Reduce Symptoms and Prevent Recurrence

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?